The online CME search engine.

The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer

Provided by:

Course Description

The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer About this course Released: 6/17/2016 Expires: 6/17/2018 Instructions Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page Study the educational activity Complete the CME quiz and evaluation After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate *The CME quiz and evaluation must be completed by June 17, 2018 in order to receive the credit or participation certificate. Target Audience Physicians who wish to advance their current knowledge of genitourinary cancer. Learning Objectives Assess the feasibility of direct prostate biopsy for PrCa in a population at high risk of PrCa due to their family history Assess the role of the currently known SNPs associated to PrCa risk in assessing the risk of the disease in a population of men with high risk of the disease Compare the predictive value of the genetic score with that of PSA and RM in this high risk population Accreditation and Credit Designation The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians. The Society for Translational Oncology designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Disclosure Policy In compliance with the ACCME Standards of Commercial Support, it is the policy of the Society for Translational Oncology to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities and to include information free of commercial bias and based on the best evidence available. All individuals in a position to influence the content of this activity have disclosed relevant financial interests or relationships of their own, their spouse/partner, or their worksite, with manufacturers or providers of commercial products, services, technology, or programs; and disclosed relationships with current non-governmental supporters of the activity. All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis. Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://authors.theoncologist.com/conflicts-of-interest. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors. Author Disclosure(s) Elena Castro Oncogenetics Team, The Institute of Cancer Research and Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Christos Mikropoulos Oncogenetics Team, The Institute of Cancer Research and Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Elizabeth K. Bancroft Oncogenetics Team, The Institute of Cancer Research and Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Tokhir Dadaev Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Chee Goh Oncogenetics Team, The Institute of Cancer Research and Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Natalie Taylor Oncogenetics Team, The Institute of Cancer Research and Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Edward Saunders Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Nigel Borley Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Diana Keating Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Elizabeth C. Page Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Sibel Saya Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Stephen Hazell Histopathology Department, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Naomi Livni Histopathology Department, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Nandiata deSouze Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, United Kingdom The author discloses no financial relationships relevant to the content of this article.   David Neal Departments of Oncology and Surgery, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Freddie C. Hamdy Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom The author discloses no financial relationships relevant to the content of this article.   The PROFILE Study Steering Committee: Pardeep Kumar Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Antonis C. Antoniou Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Zsofia Kote-Jarai Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Rosalind A. Eeles Oncogenetics Team, The Institute of Cancer Research and Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom The author discloses no financial relationships relevant to the content of this article.   Section Editor Disclosures M. Dror Michaelson discloses no relevant financial relationships. Independent Peer Reviewers Disclosures Reviewer “A” discloses no relevant financial relationships. Reviewer “B” discloses no relevant financial relationships. CME Activity Directors Disclosures Frank M. Balis, M.D., CME Program Co-Editor, Director of Oncology Clinical Research, The Children's Hospital of Philadelphia, has disclosed no financial relationships relevant to the content of these articles. Jayne S. Gurtler, M.D., F.A.C.P., CME Program Associate Editor, East Jefferson General Hospital, Metairie, Louisiana, discloses research funding from sanofi-aventis, GlaxoSmithKline, and Eli Lilly. Staff Planners Disclosures No financial relationships relevant to the content of this article have been disclosed by the staff planners. Commercial Support The Editors are grateful for educational grants from Amgen, AstraZeneca, and Taiho Oncology in partial support of our Journal CME Program. Other Links Disclaimer Privacy statement Correspondence The Oncologist CME Online 318 Blackwell Street, Suite 270 Durham, North Carolina 27701 Phone: (919) 433-0489 Fax: (919) 680-4411 Email: CME@TheOncologist.com

Ratings and Reviews

To review this course, please login.

Please Review This Course

Overall Quality

Instructor

Usefulness

150 Characters Minimum

Submit
Course Information

Overall Quality

(0)

Instructor

(0)

Usefulness

(0)
Add to Transcript Write Review

Learning Format 1 Hours
Self-Study

Credit Type(s)
Cancer Management Urology Infectious Diseases Family Medicine